The University of Kansas Health System Participates in DAWN

DAWN trialThe University of Kansas Health System joins other high-performing stroke centers in the United States and abroad in the DAWN clinical trial. The purpose of the trial is to determine if we can reliably predict which patients with acute ischemic stroke will benefit from endovascular treatment (EVT) using an embolectomy device.

In 2015, five clinical trials conclusively demonstrated that patients with large vessel occlusions (LVO) causing ischemic stroke do better when the clot is removed mechanically than when it is treated only with thrombolysis (clot busting). The next frontier is to figure out how to accurately select the LVO cases that will do well with EVT based on the pattern of the stroke rather than a strict time window.

The usual time frame for EVT is six to eight hours after onset of symptoms. In the DAWN trial, we will be enrolling patients between six and 24 hours after symptom onset based on the amount of salvageable tissue seen using specialized software (RAPID) for analysis of perfusion scans done either with MRI or CT technology. If the results are positive, our focus on strict time windows for selecting patients for treatment would shift to a more physiologic model and potentially increase the number of people we can help, including those with unknown time of onset.

For more information regarding the DAWN clinical trial, visit